This specific molecular interaction highlights the precision with which SP-D exerts its anti-leukemic effects, offering a targeted approach to leukemia treatment that holds promise for the development of effective therapeutic strategies in combating cancers such as acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and Burkitt’s lymphoma (112, 113, 119). The gene discussed is SFTPD; the disease is acute myeloid leukemia.